Trial Profile
A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled multi-center study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Muromonab CD3 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 26 Mar 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 23 Mar 2012 Additional locations identified as reported by as reported by European Clinical Trials Database.
- 23 Oct 2011 Additional trial centre and investigator identified as reported by by ClinicalTrials.gov.